UP421: Revolutionizing Diabetes Treatment Without Immunosuppression
Uppsala University Hospital and Sana Biotechnology recently announced a groundbreaking development in diabetes treatment. They have received authorization from the Swedish Medical Products Agency for a first-in-human clinical trial of UP421, a novel islet cell therapy for type 1 diabetes. This treatment, developed using Sana’s innovative hypoimmune (HIP) technology, aims to transplant functional islet cells […]